raises $5M to accelerate commercialization of Cook Regentec’s bioproduction tools
Growth capital supports current, future innovative product development and commercialization
Indianapolis, IN. – Sexton Biotechnologies announced today that it has raised $5 million in growth capital and is the first company incubated by Indianapolis-based Cook Regentec to secure outside investment capital and spin out as an independent biotechnology company. In addition to ongoing research and product development, Sexton Biotechnologies will expand and scale commercialization of its portfolio of container closure and media supplementation tools for cell and gene therapy bioproduction.
Sexton Biotechnologies products include the CellSeal platform of containers and fill systems and the Stemulate®, n-Liven PR®, and T-Liven PR human platelet lysate (hPL) products. CellSeal is based around the benefits of a rigid, cryo-compatible closed vial and the flexibility to fit into cell and gene therapy processing methods.
Sexton Biotechnology plans to continue building on its platform to bring novel solutions to cell and gene therapy manufacturing operations allowing flexible integration to accelerate process development. The line of hPL-based supplements includes a standard pooled platelet lysate, an irradiated pooled platelet lysate (PR), and the recently launched T-cell activity verified PR product.
The investment group providing growth capital for Sexton Biotechnologies includes BioLife Solutions (NASDAQ:BLFS) a leading developer and supplier of cell and gene therapy bioproduction tools, Casdin Capital, BioCrossroads and Cook Regentec.
The opportunity to work closely with partners of such deep expertise in the cell and gene therapy industry will drive new focus to continue our growth. We appreciate the support of Casdin Capital, a leading healthcare hedge fund focused on making multiple thematic investments in biotech ecosystems including the cell and gene therapy space. We’re also excited for the opportunity to work with BioLife Solutions to leverage their sales and marketing expertise and resources as we work to expand our customer base,” said Sean Werner, president of Sexton Biotechnologies.
“This new round of investment gives us additional resources to further develop and support our unique products while strengthening our connections in the thriving Indiana life sciences sector through the relationship with Biocrossroads.
Sexton Biotechnologies will be fully independent of Cook Regentec after the closing, which is scheduled for October 1, 2019.
For more information about Sexton Biotechnologies, please visit the website at www.sextonbiotechnologies.com.